Premium
Randomized comparative study of omeprazole and famotidine in reflux esophagitis
Author(s) -
Kawano Sunao,
Murata Hiroaki,
Tsuji Shingo,
Kubo Mitsuhiko,
Tatsuta Masaharu,
Iishi Hiroyasu,
Kanda Tsutomu,
Sato Tomonobu,
Yoshihara Harumasa,
Masuda Eiji,
Noguchi Masahiko,
Kashio Shinji,
Ikeda Masahiro,
Kaneko Akira
Publication year - 2002
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1046/j.1440-1746.2002.02785.x
Subject(s) - medicine , famotidine , omeprazole , reflux esophagitis , esophagitis , hiatal hernia , randomized controlled trial , proton pump inhibitor , gastroenterology , randomization , adverse effect , reflux , disease
Background: Although proton pump inhibitors (PPI) and H 2 ‐receptor antagonists (H 2 ‐RA) are routinely used in the treatment of reflux esophagitis (RE), no consensus has been reached yet as to whether the first‐choice drug should be PPI or H 2 ‐RA. In this study, the effects of omeprazole (OMP) and famotidine (FAM) on RE have been examined in a randomized comparative study. Methods: Protocols of OMP 20 mg once daily or FAM 20 mg twice daily for 8 weeks were allocated to 56 cases with RE at random, using an envelope randomization method. Their efficacy in achieving healing was examined endoscopically and a relief from subjective symptoms was compared. Results: Patient's background such as sex, age, recurrence, hiatal hernia, smoking and drinking habits, and complications, and the severity of esophagitis at the time of enrolment were not significantly different between the two groups. Healing in the OMP group and the FAM group was observed in 72 and 32% ( P = 0.025) of patients at week 4 and 95 and 53% ( P = 0.003) of patients at week 8, respectively. Subjective symptoms were relieved more frequently in the OMP group (at week 2, 67% compared with 29%, P = 0.005; at week 4, 95% compared with 55%, P = 0.009), but this superiority was not significant at week 8 (94% compared with 65%, P = 0.085). No serious adverse events occurred. Conclusions: Omeprazole provided quicker healing and a greater relief from subjective symptoms than did FAM in the treatment of RE, and was considered more suitable as a first‐choice drug. © 2002 Blackwell Publishing Asia Pty Ltd